Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant

Robert R. Redfield, Stanley C. Jordan, Stephan Busque, Flavio Vincenti, E. Steve Woodle, Niraj Desai, Elaine F. Reed, Simon Tremblay, Andrea A. Zachary, Ashley A. Vo, Richard Formica, Thomas Schindler, Ha Tran, Caroline Looney, Candice Jamois, Cherie Green, Alyssa Morimoto, Richa Rajwanshi, Aaron Schroeder, Matthew D. CascinoPaul Brunetta, Dominic Borie

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant'. Together they form a unique fingerprint.

Medicine & Life Sciences